

Curriculum Vitae et Studiorum

Matteo Ruggeri

E-mail: matteo.ruggeri@iss.it;

matteo.ruggeri@unicamillus.org

matteo.ruggeri@sorbonne.ae

EDUCATION

- March 2006: PhD in Health Economics, Università Cattolica del Sacro Cuore : Final dissertation: *Is risk attitude in health context specific?*
- March 2006: Advanced course in *Modelling Methods for Health Economic Evaluations*, Centre for Health Economics, University of York.
- June 2005 : Advanced Training in *Evaluation of Health Care*, CEIS “Tor Vergata” & Centre For Health Economics, University of York.
- December 2003: *Magister Artis* (MA) in Business Engineering, Università di Roma “Tor Vergata”.
- August 2002: Msc in Economics, Università di Roma “Tor Vergata”.
- July 2001: BA in Economics, full marks, Faculty of Economics, Università di Roma, “Tor Vergata”. Dissertation in Econometrics

VISITING EXPERIENCE

- January-March 2006: Visiting student, *Centre for Health Economics (CHE)*, University of York.
- September – December 2005: Visiting student, *Health Economics Research Unit (HERU)*, University of Aberdeen.
- September – October 2004: Visiting student, *Centre for Medical Education and Health Care*, Thomas Jefferson University, Philadelphia.

AREAS OF EXPERTISE

Cost effectiveness analysis, Bayesian decision modeling, experimental economics, risk and uncertainty analysis and quantitative methods in the field of Pharmacoeconomics, HTA, Healthcare Policy, Health Outcomes Research and Emergency Management.

SCIENTIFIC AND ACADEMIC APPOINTMENTS

- From May 2023: Research Director, permanent position, National Institute of Statistics (ISTAT), Rome;
- October 2019 – April 2023: Research Scientist, permanent position, National Centre for HTA (to December 2021) and National Center for Clinical Excellence and Quality of Care, Istituto Superiore di Sanità, Rome;
- June 2019 – to date: Adjunct Professor of Political Economics, St. Camillus International University of Health and Medical Sciences, Rome;
- May 2017 - to date: Professor On Assignment (POA) of Pharmacoeconomics, Université ParisSorbonne, Abu Dhabi (UAE);
- December 2013 - to date: National qualification for Associate Professor of Economic Policy (SECS p02), Italian Ministry of Education;
- May 2012 - May 2017: Assistant Professor of Economic Policy (SECS P02), Università Cattolica del Sacro Cuore, Rome;
- April 2010 – April 2012: research fellow in Economics, Università di Roma “Tor Vergata”;
- September 2006 – April 2012: Lecturer in Health Economics and Pharmacoeconomics, Faculty of Economics Università Cattolica del Sacro Cuore.

PREVIOUS POSITIONS

- April 2006 - March 2010 Health Economist, HTA Unit, University Hospital “A. Gemelli, Roma and Centro di Ricerche e Formazione ad Alta Tecnologia nelle Scienze Biomediche, Campobasso - Università Cattolica del Sacro Cuore;
- June 2003 – December 2005, PhD fellow Università Cattolica del Sacro Cuore, Roma;
- January 2003 – March 2003: Research assistant, CEIS, Center for International Studies on Economic Growth, Facoltà of Economia, Università di Roma “Tor Vergata”.

MILITARY EXPERIENCE

- 2021: Appointed with a 2nd class Benemerence medal as merit for service during COVID 19 pandemics;
- 2021: Appointed with military praise from the Div. General Commander in Chief of the Red corss Military Corps as merit for service during COVID 19 pandemics;
- 2016 to date: Officer, Mantainance and Administration services of the Red Cross Volunteer Military Corps - Special Rescue Units. Degree: 1st Lieutenant;

- 2012 to 2016: Officer, Maintenance and Administration services of the Red Cross Volunteer Military Corps - Special Rescue Units. Degree: Lieutenant;
- 2002 - 2012: Officer, Italian Army Reserve. Degree: 2nd Lieutenant.

INSTITUTIONAL GRANTS

- 2017 - 2020: H 2020 “IMPACT –HTA: Improved Methods and Actionable Tools for Enhancing Health Technology Assessment” Project no. 779312, co- Principal Investigator WP9, leader : “Assessing the Fiscal Impact of new medical technologies”;

2012 – 2016: FP7 “MUNROS – Health care reform: the impact on practice, outcomes and costs of new roles for health professions”. Project No. 305467. Project Management Team member and WP6 leader: the patient satisfaction. Principal Investigator: Prof. RE Elliott

TEACHING

- 2019 to date: Economic Policy (SECS P02) and Applied Economics (SECS P06): BA in Medicine and Surgery (English), BA programs in Nursing, Physiotherapy (English), Midwifery, Biomedical Laboratory, Radiology, Msc in Management for health professionals, St. Camillus International University of Health Sciences in Rome (approx. 240 hours/year);
- 2017 to date: Decisions in HTA, Msc in Health Economics (English), Paris Sorbonne Abu-Dhabi (approx. 40 hours/year);
- 2011 to date: Health Economics and Pharmacoeconomics, MA programs in HTA, Market Access, Evaluation of Healthcare, Health Policy and Emergency Management, ALTEMS/ Ce.Ri.S.Ma.S – Postgraduate School/Centre for Research in Health Economics and Management, Università Cattolica del Sacro Cuore, Rome and Milan (approx. 90 hours/year);
- 2008 to date: Evaluation of healthcare, MA in Health economics and management, Università G.D’Annunzio, Pescara (approx. 9 hours/year);
- 2006 to 2019: Economic Policy, Health Economics and Pharmacoeconomics (English), BA and MSc in Health economics and Management, Faculty of Economics, Università Cattolica del Sacro Cuore (total 180 hours/year);
- 2012 to 2017: Chief of the Health Economics and HTA Program, ALTEMS/ Ce.Ri.S.Ma.S – Postgraduate School/Centre for Research in Health Economics and Management, Università Cattolica del Sacro cuore, Rome and Milan;
- 2014 to 2017: Director of the post graduate programs in: Decision Modeling for Health Economic Evaluations and Emergency Management;

- 2003 to 2010: Health economics and management, BA and Msc courses in nursing and midwifery, Università Cattolica del Sacro Cuore, Istituto figlie di San Camillo, Rome and Rieti.

PROFESSIONAL EXPERIENCE

- 2019 to date: scientific advisor, private funded research projects in the field of pharmacoeconomics and decision modelling for health economics evaluations for pharma, medical devices and consulting companies, Health Economics Evaluation (HEE) Unit, St. Camillus International University of Health Sciences in Rome;
- 2006-2017 : scientific advisor, private funded research projects in the field of pharmacoeconomics and decision modelling for health economics evaluations, scientific advisor for pharma, medical devices and consulting companies, ALTEMS/ Ce.Ri.S.Ma.S – Postgraduate School/Centre for Research in Health Economics and Management, Università Cattolica del Sacro cuore, Rome and Milan.

CHAIR OF INTERNATIONAL CONFERENCES

- 2ND ECONOMICS OF THE HEALTH WORKFORCE CONFERENCE. Aula Cripta, Università Cattolica del Sacro Cuore, Milano 11-12 Luglio 2015

PUBLICATIONS

Special Issues Editor

- Cadeddu C., Ruggeri M., Marchetti M. (2020) *Special issue on HTA*. Journal of Enviromental and Public Health
- Ruggeri M. (2016). *Special Issue on Health Economics*. Rivista Internazionale di Scienze Sociali. N.34 pp 235-398

Articles on international, peer reviewed journals

- Ruggeri M, Signorini A, Caravaggio S. *Casirivimab and imdevimab: Cost-effectiveness analysis of the treatment based on monoclonal antibodies on outpatients with Covid-19*. PLoS One. 2023 Feb 10;18(2):e0279022. doi: 10.1371/journal.pone.0279022. PMID: 36763607; PMCID: PMC9916561.
- Drago C, Gatto A, Ruggeri M, *Telemedicine as technoinnovation to tackle COVID-19: A bibliometric analysis*. Technovation, 2023, 102417, ISSN 0166-4972, <https://doi.org/10.1016/j.technovation.2021.102417>.
- Ruggeri M, Signorini A, Caravaggio S, Alraddadi B, Alali A, Jarrett J, Kozma S, Harfouche C, Al Musawi T. *Modeling the Potential Impact of Remdesivir Treatment for Hospitalized Patients with COVID-19 in Saudi Arabia on Healthcare Resource Use and Direct Hospital Costs: A Hypothetical Study*. Clin Drug Investig. 2022 Aug;42(8):669-678. doi: 10.1007/s40261-022-01177-z. Epub 2022 Jul 15. PMID: 35838880; PMCID: PMC9284952.

- Ruggeri M, Signorini A, Caravaggio S, Rua J, Luís N, Braz S, Aragão F. *Estimation Model for Healthcare Costs and Intensive Care Units Access for Covid-19 Patients and Evaluation of the Effects of Remdesivir in the Portuguese Context: Hypothetical Study*. Clin Drug Investig. 2022 Apr;42(4):345-354. doi: 10.1007/s40261-022-01128-8. Epub 2022 Mar 17. PMID: 35298832; PMCID: PMC8928238.
- Ruggeri M, Donatella M, Federica C, Salvatore D, Costanza S, Marta C, Paolo R, Marco M. *The transcatheter aortic valve implantation: an assessment of the generalizability of the economic evidences following a systematic review*. Int J Technol Assess Health Care. 2022 Mar 24;38(1):e27. doi: 10.1017/S0266462321001720. PMID: 35321767.
- Gatto A, Drago C, Ruggeri M. *On the Frontline-A bibliometric Study on Sustainability, Development, Coronaviruses, and COVID-19*. Environ Sci Pollut Res Int. 2022 Mar 6:1–17. doi: 10.1007/s11356-021-18396-0. Epub ahead of print. PMID: 35249187; PMCID: PMC8898194.
- Ruggeri M, Drago C, Mandolini D, Francesa Morel P, Mencacci C, Starace F. *The costs of treatment resistant depression: evidence from a survey among Italian patients*. Expert Rev Pharmacoecon Outcomes Res. 2022 Apr;22(3):437-444. doi: 10.1080/14737167.2021.1954507. Epub 2021 Jul 26. PMID: 34240678.
- Latina R, Iacorossi L, Fauci AJ, Biffi A, Castellini G, Coclite D, D'Angelo D, Gianola S, Mari V, Napoletano A, Porcu G, Ruggeri M, Iannone P, Chiara O, On Behalf Of Inih-Major Trauma. *Effectiveness of Pre-Hospital Tourniquet in Emergency Patients with Major Trauma and Uncontrolled Haemorrhage: A Systematic Review and Meta-Analysis*. Int J Environ Res Public Health. 2021 Dec 6;18(23):12861. doi: 10.3390/ijerph182312861. PMID: 34886586; PMCID: PMC8657739.
- Pietrantonio F, Rosiello F, Alessi E, Pascucci M, Rainone M, Cipriano E, Di Berardino A, Vinci A, Ruggeri M, Ricci S. *Burden of COVID-19 on Italian Internal Medicine Wards: Delphi, SWOT, and Performance Analysis after Two Pandemic Waves in the Local Health Authority "Roma 6" Hospital Structures*. Int J Environ Res Public Health. 2021 Jun 3;18(11):5999. doi: 10.3390/ijerph18115999. PMID: 34204972; PMCID: PMC8199852.
- Ruggeri M, Signorini A, Caravaggio S, Santori C, Rosiello F, Coluzzi F. *Cost-Effectiveness Analysis of Tapentadol Versus Oxycodone/Naloxone in both Branded and Generic Formulations in Patients with Musculoskeletal Pain*. Clin Drug Investig. 2021 Oct;41(10):875-883. doi: 10.1007/s40261-021-01074-x. Epub 2021 Sep 15. PMID: 34524651.
- Ruggeri, M., Drago, C. (2021). *Is risk attitude toward health outcomes context driven?*. Quality and Quantity. <https://doi.org/10.1007/s11135-020-00993-93>
- Ruggeri M, Cadeddu C, Roazzi P, Mandolini D, Grigioni M, Marchetti M. *Multi-Criteria-Decision-Analysis (MCDA) for the Horizon Scanning of Health Innovations an Application to COVID 19 Emergency*. Int J Environ Res Public Health. 2020 Oct 26;17(21):7823. doi: 10.3390/ijerph17217823. PMID: 33114587; PMCID: PMC7662805.

- Ruggeri, M., Drago, C., Cadeddu, C., Armuzzi, A., Leone, S., & Marchetti, M. (2020). The Determinants of Out-of-Pocket Expenditure in IBD Italian Patients. Results from the AMICI Survey. *International journal of environmental research and public health*, 17(21), 8156. <https://doi.org/10.3390/ijerph17218156>
- Coretti S., Ruggeri M., Dibidino R., Gitto L., Marcellusi A., Mennini F.S., Cicchetti A. (2020) *Economic evaluation of colorectal cancer screening programs: Affordability for the health service*. Journal of medical screening 10.1177/0969141319898732", "https://www.scopus.com/inward/record.uri?eid=2-s2.0-
- Ruggeri, M., Di Brino, E., & Cicchetti, A. (2020). *Estimating the fiscal impact of three vaccination strategies in Italy*. Int J Technol Assess Health Care 36(2), 133-138. doi:10.1017/S0266462320000069
- Ruggeri, M., Drago, C., Rosiello, F. et al. (2020) *Economic Evaluation of Treatments for Migraine: An Assessment of the Generalizability Following a Systematic Review*. Pharmacoeconomics 38, 473–484. <https://doi.org/10.1007/s40273-019-00879-1>
- Carletto A, Cicchetti A, Coretti S, Moramarco V, Ruggeri M (2019). *Money back guarantee? A cost-benefit framework of performance-based agreements (PBAs) for the reimbursement of pharmaceuticals* . Eurasian Business Review, vol. 9, p. 89-101, ISSN: 1309-4297
- Drago C, Ruggeri M (2019). *Setting research priorities in the field of emergency management: which piece of information are you willing to pay more?* Quality and Quantity, ISSN: 1573-7845, doi:10.1007/s11135-019-00858-w
- Ruggeri M, Rolli, FR, Kondili, LA, (...), Nappi C, Cicchetti A. (2019). *Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy* . Expert review of pharmacoeconomics and outcomes research, ISSN: 1473-7167, doi: DOI: 10.1080/14737167.2019.1537784
- Ruggeri M, Romano F, Basile M, Coretti S, Rolli FR, Drago C, Cicchetti A. *Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy*. Appl Health Econ Health Policy. 2018 Oct;16(5):711-722. doi: 10.1007/s40258-018-0410-x. PMID: 30039348.
- Caraceni P, Riggio O, Angeli P,... Ruggeri M et al. (2018). *Long term albumin administration in decompensated cirrosi. An oend label randomized trial*. The Lancet. Vol391, N. 10138, p2417–2429,
- Rolli FR, Ruggeri M, Kheiraoui F, Drago C, Basile M, Favaretti C, Cicchetti A. *Economic evaluation of Zepatier for the management of HCV in the Italian scenario*. Eur J Health Econ. 2018 Dec;19(9):1365-1374. doi: 10.1007/s10198-018-0980-4. Epub 2018 Apr 25. PMID: 29696459.
- Ruggeri M, Basile M, Rolli FR, Drago C, Cicchetti A. (2018). *Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy*. Pharmacoeconomics. DOI: 10.1007/s40273-018-0643-4

- Ruggeri M, Romano F, Coretti S, Kondili, Vella S, Cicchetti A. (2018) *Economic evaluation of the HCV treatment extension to early stage fibrosis patients. Evidence from the PITER real world cohort.* In press, Value in Health. DOI: <https://doi.org/10.1016/j.jval.2017.10.021>
- Kondili LA, Romano F, Rolli FR, Ruggeri M et al. (2017) *Modeling cost effectiveness and health gains of a “universal” versus “prioritized C virus treatment policy in a real life cohort.* Hepatology, Jul 24. DOI:10.1002/hep.29399
- Gitto L., Ruggeri M., Mennini FS., Coretti S., Buscema PM., et al. (2017) *Does regional belonging explain the similarities in the expenditure determinants of Italian healthcare deliveries? An approach based on Artificial Neural Networks .* Economic Analysis and Policy 55: 47-56
- Sirven N., Rapp T., Coretti S., Ruggeri M., Cicchetti A. (2017) *Preventing mobility disability in Europe: a health economics perspective from the SPRINTT study.* Aging Clin Exp Res. Feb 3. doi: 10.1007/s40520-016-0713-4.
- Ruggeri, M. Basile M., Drago C., Coretti S., Cicchetti A. (2017) *Economic analysis and budget impact of Tenofovir and Entecavir for the treatment of HBV in Italy.* Applied Health Economics and Healthcare Policy Aug;15(4):479-490. doi: 10.1007/s40258-017-0311-4
- Cicchetti A, Berrino A, Casini M, Codella P, Facco G, Fiore A, Marano G, Marchetti M, Midolo E, Minacori R, Refolo P, Romano F, Ruggeri M, Sacchini D, Spagnolo AG, Urbina I, Vaglio S, Grazzini G, Liembruno GM. (2016) *Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use.* Blood Transfus. 14(4):287-386. doi: 10.2450/2016.0065-16. Review.
- Ruggeri M. (2016). *Introduction to Essay Health and Economics.* Rivista Internazionale di Scienze Sociali. N.3-4 pp 235 – 238
- Bond C, Bruhn H, de Bont A, van Exel J, Busse R, Sutton M, Elliott R; MUNROS team (2016) *The iMpaCt on practice, oUtcomes and costs of New roles for health pROfeSSionals: a study protocol for MUNROS.* BMJ Open. 2016 Apr 26;6(4):e010511. doi: 10.1136/bmjopen-2015-010511.
- Moramarco V., Ruggeri M.. (2016). *Between Rationing and Rationalization. The challenges of the Italian National Health Service during the age of the great crisis.* Rivista Internazionale di Scienze Sociali. N3-4, pp 349-364
- Ruggeri M., Coretti S., De Waure C., Cicchetti A. (2016). *Healthcare expenditure of prevention in the spending review era.* Rivista Internazionale di Scienze Sociali. N.-3-4, pp.365-384
- Ruggeri M, Coretti S, Romano F. (2016) *Economic assessment of Zostavax vaccine for the prevention of Herpes Zoster.* International Journal of Technology assessment in Healthcare. 32 (3)
- Ruggeri M, Aiello A, D'Ausilio A, Di Brino E et al. (2016) *Evolution of the healthcare expenditure in*

Italy and effects of fingolimod increased prescribing in second line treatment of relapsing-remitting multiple sclerosis. Global and Regional HTA, 3(3): 125 - 133

- Mennini FS, Gitto L, Scrivo R, Drago F, Iezzi M, Terranova L, Ruggeri M et al. (2016) *The promotion of drug innovation in Italy: critical aspects and unsolved problems.* Global and Regional HTA3(1) 42-47
- Fanelli A, Ruggeri M, Basile M, Cicchetti A et al. (2016) *Activity-based costing analysis of the analgesic treatments used in postoperative pain management in Italy.* Minerva Medica 107(1): 1-13
- Buscema PM, Maurelli G, Mennini FS, Gitto L, Russo S, Ruggeri M, Coretti S, Cicchetti A.(2016) *Artificial neural networks and their potentialities in analyzing budget health data: an application for Italy of what-if theory.* Quality and Quantity. doi:10.1007/s11135-016-0329-y
- Rossitto C, Gueli Aletti T, Ruggeri M, Romano F et al. (2016). *Use of robot-specific resources and operating room times: the case of Telelap Alf-X robotic hysterectomy.* International Journal of Medical Robotics and Computer Assisted Surgery. DOI: 10.1002/rcs.1724
- Marietta M, Franchini M, Bindi ML, Picardi F, Ruggeri M (2016). *Is solvent/detergent plasma better than standard fresh-frozen plasma? A systematic review and an expert consensus document.* Blood Transfusion, 4(4):277-286
- Menditto E, Orlando V, Coretti S, Putigano D, Fiorentino D, Ruggeri M. (2015) *Doctors' commitment and long term effectiveness for cost containment policies: lessons learned from biosimilar drugs.* Clinicoeconomics, 27 October
- Gasparini R, Mennini FS, Panatto D, Bonanni P, Cicchetti A, Ruggeri M et al. (2015). *How can the results of Health Technology Assessment (HTA) evaluations applied to vaccinations be communicated to decisionmakers and stakeholders? The ISPOR Rome Chapter Project.* Journal of Preventive Medicine and Hygiene 56: E150-4
- Coretti S, Romano F, Orlando V, Codella P, Prete S, Di Brino E, Ruggeri M. (2015) *Economic evaluation of screening programs for hepatitis C virus infection: evidence from literature.* Risk Manag Healthc Policy. Apr 21;8:45-54.
- Romano F, Ruggeri M, Coretti S et al. (2015) *Economic assessment of eltrombopag in the treatment of thrombocytopenia.* Expert Rev Pharmacoecon Outcomes Res.15(4):713-20.
- Panichi V, Rosati A, Di Giorgio A, ..., and Ruggeri M (2015). *A pharmacoeconomic analysis of phosphate binders cost-effectiveness in the RISCVID study.* Blood Purif 2015;39(1-3):174-80
- Dibidino R, Quartuccio L, Ruggeri M (2015). *Cost-effectiveness analysis of two Rituximab retreatment regimens for longstanding rheumatoid arthritis.* Arthritis Care and Research 2015 Jul;67(7):947-55.
- Coretti S, Ruggeri M (2015). *Normative needs in healthcare: toward a new conceptualization of equity and capabilities.* Rivista Internazionale di Scienze Sociali, 2014, n. 4, pp. 383-400.

- Ruggeri M, Manca A, Coretti S et al. (2015). *Investigating the generalizability of Economic Evaluations conducted in Italy: a critical review*. Value in Health (18):709-20. - Ruggeri M, Coretti S (2015). *Do Probability and Certainty Equivalent techniques lead to inconsistent results? Evidence from gambles involving life years and quality of life*. Value in Health (18):413-24.
 - Ruggeri M, (2014). *The cost effectiveness of Botox in Italian patients with chronic migraine*. Neurol Sci 35 (Suppl 1):S45–S47
 - Ruggeri M, Bellasi A, Cipriani F, Molony D, Bell C, Russo D, Di Iorio B. (2014). *Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study*. J Nephrol. Jul 16
 - Ruggeri M, Cipriani F, Bellasi A, Russo D, Di Iorio B (2014) . *Sevelamer Is Cost-Saving vs. Calcium Carbonate in Non-Dialysis-Dependent CKD Patients in Italy: A Patient-Level Cost-Effectiveness Analysis of the INDEPENDENT Study*. Blood Purif;37:316–324
 - Coluzzi F, Ruggeri M (2014). *Clinical and economic evaluation of tapentadol ER and oxycodone/naloxone*. Current Medical Research and Opinion 30(6):1139-51.
 - Ruggeri M, Turriziani A, Oradei M (2014). *Cost effectiveness analysis of transnasal fentanyl citrate in the treatment of BTcP*. Expert Review of Pharmacoeconomics and Outcomes Research 14(3):459-64.
 - Coretti S, Ruggeri M, Mc Nameee P (2014). *The minimum clinically important difference of the EQ-5D index*. Expert Review of Pharmacoeconomics and Outcomes Research 14(2): 221-233.
- Ruggeri M, Coretti S, Gasbarrini A, Cicchetti A (2013) *Economic assessment of an anti HCV program in Italy*. Value in Health 16: 965-972.
- Ruggeri M, Frati F, Puccinelli P et al. (2013) *Economic Evaluation of 5-Grass Pollen Tablets Versus Placebo in the Treatment of Allergic Rhinitis in Adults*. Clinical Drug Investigation 3(5): 343-349.
- Cammà C, Petta S, Cabibbo G, Ruggeri M et al. (2013) *Cost effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C*. Journal of Hepatology_Oct;59(4):658-66.
 - Ruggeri M, van der Pol M, (2012) *Is risk attitude really specific within the health context domain? Further evidence from an Italian survey using Probability Equivalent technique and face-to face interviews*. Health Risk and Society 14:7-8, 655-666.
 - Ruggeri M, Dibidino R, Cicchetti A, Marchetti M et al.(2012) *The cost effectiveness of the Harmonic Scalpel in total thyroidectomy*. International Journal of Technology Assessment in Health Care, 28 (3): 259-64.
 - Ruggeri M, *Hepatocellular Carcioma: cost effectiveness of screening. A systematic review*.(2012) Journal of risk management and healthcare policy, 5.

- Ruggeri M, Cicchetti A, Gasbarrini A.(2011) *The cost effectiveness of alternative strategies against HBV in Italy*. Health Policy; 102(1):72-80.
- Cicchetti A., Ruggeri M, Mennini FS, Gitto L.(2010) *Extending FLU vaccination to individuals aged 50-64 in four EU countries. Social savings and Budget Impact Analysis*. International Journal of Technology Assessment in Health Care, Vol 26 (3):288-93.
- Tumbarello M, Spanu T, Dibidino R, Marchetti M, Ruggeri M et al (2010), *Costs of Bloodstream Infections Caused by Escherichia coli and Influence of Extended-Spectrum-Beta-Lactamase Production and Inadequate Initial antibiotic Therapy*. Antimicrobial Agents and Chemotherapy, p. 4085-4091.
- van der Pol M., Ruggeri M. (2008), *Is risk attitude specific within the health domain?* Journal of Health Economics 27: 706-717.

Other publications on national, indexed journals

- Ruggeri M. (2020). *Logiche di integrazione e coordinamento nella gestione dell'emofilia. L'esperienza della Regione Puglia*. Politiche Sanitarie - Italian Journal of Health Policy 21(2): 81-89
 - Ruggeri M, Cicchetti A, Coretti S, Gasbarrini A et al. (2014) *Il modello WEF per la valutazione economica delle innovazioni terapeutiche in epatologia*. Farmeconomia. Health economics and therapeutic pathways; 15(3): 75-84
 - Ruggeri M, Coretti S, Carletto A, Marchetti M (2013). *Valutazione economica di Teysuno nel trattamento del Carcinoma gastrico avanzato* . PharmacoEconomics – Italian Research Articles: 15(2) 65-75
 - Ruggeri M, Carletto A, Marchetti M (2013). *Valutazione economica della tossina botulinica per la profilassi dell'emicrania cronica*. PharmacoEconomics – Italian Research Articles 15(1): 19-33
 - Ruggeri M, Coretti S, Dibidino R et al. (2012) *Valutazione economica dei programmi di screening contro il cancro del colon retto: evidenze indirette di lungo periodo e sostenibilita` finanziaria in un'ottica di programmazione regionale* . PharmacoEconomics – Italian Research Articles 2012; 14 (2): 1-20
 - Cicchetti A, Ruggeri M, Coretti S et al., (2011) *Valutazione economica di un programma di screening antiHCV in Italia*. PharmacoEconomics – Italian Research Articles 13 (2): 1-19
- Cicchetti A, Ruggeri M, Codella P, Ridolfi A (2011). *I costi socio sanitari dell'insufficienza renale cronica*. Farmeconomia e percorsi. 12(1): 21-28;
- Dibidino R, Ruggeri M, Cicchetti A et al. (2010) *Valutazione costo efficacia del bisturi ad ultrasuoni Harmonic Scalpel per gli interventi di tiroidectomia totale*. PharmacoEconomics – It. Res. Art. 12 (3): 113
- Dibidino R., Ruggeri M, Cicchetti A. (2010). *Valutazione dei costi delle infezioni nosocomiali da E.Coli in un policlinico romano di 1700 posti letto* . PharmacoEconomics – Italian Res- Art. 12(2): 81-90
- Gruppo di lavoro AIES coordinato da Giovanni Fattore (2009). *Proposta di linee guida per la valutazione economica degli interventi sanitari*. PharmacoEconomics – Italian Res. Art., Vol. 11(2)

- Cicchetti A., Ruggeri M., Gasbarrini A (2009). *Valutazione costo-efficacia del percorso di pazienti a rischio di epatite B sottoposti a test anti – HBV*. Pharmacoeconomics – Italian Res. Art., Vol. 11(2).
- Cicchetti A., Ruggeri M (2009). *Valutazione economica di Ranibizumab vs Pegaptanib o vs terapia fotodinamica con Verteporfin*. Italian Journal of Public Health, 6(2), suppl. 3 S31:S44.
- Cicchetti A., Ruggeri M, Mennini FS, Gitto L. (2009). *Analisi economica per l'estensione della vaccinazione contro l'influenza: i risultati di una simulazione*. Pharmacoeconomics – Italian Res. Art..
- A. Cicchetti, A. Manca, M. Ruggeri (2007). *L'utilizzo di modelli decisionali per le valutazioni economiche dei farmaci in Italia: stato dell'arte e prospettive future*, Pharmacoeconomics – Italian Research Articles 9 (2), 59-74.
- A. Cicchetti, P. Papini, M. Ruggeri, A. De Luca, D. Mascia, E. Cipolloni, G. Guasticchi (2006). *L'analisi dei network organizzativi nei sistemi sanitari: il caso della rete di emergenza nella regione Lazio*, Politiche Sanitarie, Vol. 7(2)
- L. Piasini, M. Ruggeri, F. Spandonaro (2002). *Le politiche per l'assistenza ospedaliera nelle regioni italiane*, Rapporto CEIS Sanità 2002.

Book chapters

- Ruggeri M, Mennini FS, Buscema P, Cicchetti A, et al. *Analisi degli sprechi in sanità e stima economica dell'impatto della corruzione*. In: AA.VV. Libro Bianco sulla corruption in Sanità. ISPE (Istituto per la Promozione dell'Etica in Sanità), Roma, Aprile 2014.
- Ruggeri M, Mennini FS, Buscema P, Cicchetti A, et al. *Modello di individuazione degli sprechi e della corruption in Sanità. Un approccio basato sulle reti neurali artificiali* In: AA.VV. Libro Bianco sulla corruption in Sanità. ISPE (Istituto per la Promozione dell'Etica in Sanità), Roma, Aprile 2014.
- Ruggeri M, *Le valutazioni economiche nell'HTA*. In: Cicchetti A, Marchetti M, Manuale di Health Technology Assessment. Il pensiero scientifico, Roma Ottobre 2010;
- Marchetti M, Cicchetti A, Leogrande L, Ruggeri M et al. *Il ruolo dell'HTA nella gestione ospedaliera: il caso del Policlinico "A. Gemelli"*. In: Cicchetti A, Marchetti M, Manuale di Health Technology Assessment. Il pensiero scientifico, Roma Ottobre 2010;
- AG De Belvis, M. Ruggeri, A. Cicchetti et al, *Costi social dell'obesità infantile*. In: A. Spagnolo, E. Menghetti, *Soprapeso ed obesità nell'età evolutiva: vera epidemia sociale del terzo millennio*. Istituto per gli affari sociali, Roma, Aprile 2008.

Press

- M. Ruggeri, A. Palmieri e C. Drago. *La contagiosità sociale del panico*. Vita, 30 maggio 2020

- A. Palmieri e M. Ruggeri. *La medicina territoriale come secondo pilastro del Servizio Sanitario Nazionale*. OpenCalabria, 24 Maggio 2020
- M. Ruggeri, A. Palmieri e C. Drago. *L'economia ai tempi del Coronavirus, provando ad immaginare il domani*. OpenCalabria, 14 Aprile 2020.
- M. Ruggeri. *I criteri per effettuare una valutazione economica dei PDTA per la gestione dei pazienti con HIV*. In: Il percorso diagnostico terapeutico dell'HIV, relazione fra innovazione di processo e cambiamento organizzativo per la valutazione degli outcomes e delle performances della malattia da HIV. Il sole 24 ore sanità Gennaio 2014
- M. Ruggeri, A. Cicchetti, S. Coretti, *Valutazione economica pre-HTA della triplice terapia con nuove molecole in pazienti "non responders"*. In: Il trattamento delle epatiti virali in Italia: sostenibilità di un modello vincente. Il sole 24 Ore Sanità – i quaderni di medicina. Aprile 2012
- M. Ruggeri, S. Coretti, A. Cicchetti et al., *Screening anti-Hcv: ipotizzato un costo di 47 milioni per individuare e trattare 554 mila soggetti a rischio*. In: Dalle epatiti all'epatocarcinoma, epidemiologia e costi associati. Il sole 24 Ore Sanità – i quaderni di medicina. Giugno 2011.
- A. Cicchetti, M. Ruggeri, *Analisi costo-benefici basate su trial clinici randomizzati per la scelta di interventi mirati in prevenzione e terapia*. In: Costruire insieme salute: prospettive, efficacia e sostenibilità di un modello di disease e care management in prevenzione cardiovascolare. Il sole 24 Ore Sanità – i quaderni di medicina. Novembre 2010.

PRESENTATIONS

Most important:


- M. Ruggeri. *Health Economics and COVID – 19 Pandemics: learning from others*. Webinar organized by Clinacademy and French Chamber of Commerce in Egypt. 19th August 2020.
- M. Ruggeri. *How the Italian Health Workforce reacted to the COVID-19 Pandemics?* International Health Economics Association – Health Workforce. Special Interest Group. iHEA Webinar, June 2020
- M. Ruggeri, *The Multicriteria decision analysis. Evidences from the MUNROS Project*. MUNROS FP7 Final conference, Edimburgh, 7th February, 2017
- M. Ruggeri, *The use of artificial Neural Networks to investigate the determinants of healthcare expenditure*. iHEA conference, sessione organizzata, Università Commerciale Bocconi, Milano 13-15 Luglio 2015
- M. Ruggeri, *Money back guarantee? A cost benefit framework of performance-based agreements for the reimbursement of pharmaceuticals*. iHEA conference, sessione organizzata, Università Commerciale Bocconi, Milano 13-15 luglio 2015
- M. Ruggeri, *MUNROS project, the first results of a pilot study*. iHEA conference, sessione organizzata, Università Commerciale Bocconi, Milano 13-15 luglio 2015

- M.Ruggeri, Who cares the caregivers? The 2nd Economics of the Health Workforce Conference, Milano, Università Cattolica del Sacro Cuore 11-12 luglio 2015
- M. Ruggeri, *La valutazione economica di un programma di screening per il cancro al colon retto: evidenze dalla regione Abruzzo*. Conferenza AIES, Napoli 19-21 settembre 2011
- M. Ruggeri, *La valutazione economica di un programma di disease management per la prevenzione delle malattie cardiovascolari*. Conferenza AIES, Napoli 19-21 settembre 2011
- M. Ruggeri, La generalizzabilità delle valutazioni economiche in Italia. Conferenza AIES, Napoli 19-21 settembre 2011
- M.Ruggeri. *The cost effectiveness of a Disease Management program in Italy*. IHEA conference. Toronto 10-15 luglio 2011
- M. Ruggeri. *Valutazione dei costi delle infezioni nosocomiali da E.Coli in un policlinico romano di 1700 posti letto*. Conferenza AIES, Torino 30 settembre – 1 ottobre 2010;
- M. Ruggeri. *Is risk attitude really really specific in health care domain? Further evidence from an italian sample using different elicitation techniques*. ECHE conference, Helsinki 7-9 Luglio 2010;
- M. Ruggeri. *I costi sociali dell'Artrite Reumatoide in Italia: un modello di simulazione*. Relazione invitata al 34 convegno della società italiana di Farmacologia, Rimini 14-17 Ottobre 2009. Relazione presentata al Convegno annuale AIES. Bergamo 28-29 ottobre 2009;
- M. Ruggeri. *Is risk attitude really specific in health care domain? Further evidence from an Italian sample using PE elicitation technique and face-to-face interviews*. IHEA annual conference, Beijing, 10-16 Luglio 2009;
- M. Ruggeri. *Analisi costo-efficacia di un programma di screening. Il caso del test anti HBV*. Relazione invitata al convegno nazionale della Società Italiana di Health Technology Assessment, Roma 45 giugno 2009;
- M.Ruggeri. *Valutazione dei costi delle infezioni nosocomiali da Escherichia Coli*. 8 Convegno Nazionale di Farmacoeconomia, Milano 21-22 Maggio 2009;
- M. Ruggeri, *Valutazione economica dei trattamenti contro la degenerazione maculare senile*. 8 Convegno Nazionale di Farmacoeconomia, Milano 21-22 Maggio 2009;
- M. Ruggeri, A Cicchetti, FS Mennini, L Gitto: *Extending FLU vaccination to individuals aged 50-64 in four EU countries. Social savings and Budget Impact Analysis*. Conferenza ECHE 2008, Roma, 2326 Luglio 2008;

- M. Ruggeri, *L'uso di Harmonic Scalpel nella tiroidectomia totale: studio cost-effectiveness nella realtà italiana*, 7 Convegno nazionale di farmacoeconomia, Milano 9-10 Giugno 2008;
- M. Ruggeri, *Analisi costo-efficacia dell'evoluzione del percorso dei pazienti con HBV sottoposti a test di screening*. Convegno nazionale di farmacoeconomia, Milano 9-10 Giugno 2008;
- M Ruggeri, M. van der Pol, *L'attitudine al rischio individuale nelle scelte sanitarie. Presentazione orale*, Conferenza SIHTA 2008, Roma 8-9 Febbraio 2008;
- M Ruggeri, M. van der Pol, *L'attitudine al rischio individuale nelle scelte sanitarie. Presentazione orale*, Conferenza AIES 2007, Firenze 18-19 Ottobre 2007;
- A. Cicchetti, M. Marchetti, M. Ruggeri, M. Oradei, R. Dibidino, *Analisi costo-efficacia della politica di vaccinazione contro l'Herpes Zoster in Italia: risultati preliminari di uno studio pilota*. Presentazione orale al 6 Convegno Nazionale di Farmacoeconomia, Milano 25-26 Giugno 2007;
- A. Cicchetti, A. Manca, M. Ruggeri, *L'utilizzo di modelli decisionali per le valutazioni economiche dei farmaci in Italia: stato dell'arte e prospettive future*. Presentazione orale, Conferenza AIES 2006, Venezia 16-17 Novembre 2006;
- M. van der Pol, M. Ruggeri, *Is risk attitude in health context specific?* Presentazione orale ECHE (European Conference of Health Economics), Budapest 6-9 Luglio, 2006;
- A. Cicchetti, E. Cipolloni, D. Mascia, M. Ruggeri, *La rete dei servizi di emergenza della Regione Lazio, caratteristiche e considerazioni*. Presentazione orale, Conferenza AIES 2005, Genova, 11 – 12 Novembre 2005;
- A. Cicchetti, E. Cipolloni, D. Mascia, M. Ruggeri, *Inter-organizational Networks in Health Care. Empirical Evidences on an Italian Region*. Presentazione orale, EHMA conference, Barcellona, 29 June – 1 July 2005.

MEMBERSHIPS

- Academic editor, Plos One, 2021 to date;
- Editorial board member of Clinical Drug Investigation 2021 – to date;
- Scientific committee 2020 – to date, Italian Society for HTA (SIHTA);
- General elected secretary 2017 – 2020, ISPOR Italian chapter;
- 2008 - 2016: editorial board of Pharmacoeconomics Italian Research Articles;



Rome, 14/03/2023

